Wound Care
Mölnlycke is a leading global provider of wound care products and therapy-based solutions.
Find jobs, latest news, our financial reports and more.
Get knowledge, learn about our products, get support and more.
Watch our video to find out more.
Mölnlycke Health Care is a world-leading MedTech company that specialises in sustainable solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, healthcare providers and patients in over 100 countries around the world.
Mölnlycke applies a customer-centric approach to ensure we provide relevant solutions for the future and continue to make a difference for customers and patients.
Read moreOur expertise extends across wound care, operating room solutions, antiseptics and gloves.
Sustainability is a strategic priority at Mölnlycke and WeCare is our Sustainability roadmap for 2030. It means creating shared value for all our stakeholders. It is a driver for growth, innovation and productivity and an essential part of our employee value proposition.
How we work with sustainabilityWhy we go to work and what a career at Mölnlycke can offer. Do YOU want a career that matters?
CareersMölnlycke products and solutions are used daily by hospitals, healthcare providers and patients in over 100 countries around the world. Visit your country site to learn more.
The bond was more than five times oversubscribed with an orderbook of over EUR 2,700M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics 18%, France 12% and Other 10%. Asset Managers represented 87% of investors, followed by Insurance and Pension Funds with 9% and Banks with 4%. The proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding EUR 500M notes maturing in 2025 as well as for general corporate purposes. The bond further extends the duration of Mölnlycke’s well-spread debt maturity profile. The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange. BNP Paribas, ING, JP Morgan and SEB acted as joint bookrunners for the transaction.
Mölnlycke intends to issue a new 10-year EUR bond under its Euro Medium Term Note (EMTN) programme. The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange. At the same time Mölnlycke invites its holders of the outstanding EUR 500m bond due February 2025 note to tender any and all of their notes for purchase by the company. Read the full announcement here.
Since 1977, Phoenix Society has served burn survivors, their loved ones, burn care professionals, researchers and others committed to empowering the burn community to enable transformational healing. With the overarching vision of uniting the voice of the burn community globally to “advance lifelong healing, optimal recovery, and burn prevention”, the Phoenix Society offers programmes, tools, education and events to bring this vision to life. With our wide range of burn care solutions including for example cleansing, gentle wound dressings and scar management, Mölnlycke is uniquely positioned to support Phoenix Society initiatives. Our advanced wound care dressings are enabled by Safetac® technology, a gentle silicone adhesive that reduces pain and minimises skin trauma of burn survivors at dressing change. Mölnlycke also provide information about burn dressings and healing through educational content, clinical evidence, and tips and tricks on how to apply burn care. Inline quote: Anders Andersson The power of partnership The partnership between Phoenix Society and Mölnlycke brings together two organisations driven by a mission to make survivors’ healing easier and their lives fuller by reaching survivors earlier, minimising the impact of burns and giving survivors the solutions, resources and community needed to facilitate recovery and support.
The Tamer Mölnlycke Care joint venture was initiated in 2021 with the agreement to develop a customised surgical procedure tray factory in Saudi Arabia, with first production expected in Q4 2024. The increased investment allows for an expansion in the range of Mölnlycke products manufactured and distributed in the country and to the neighbouring region. Adding drapes and gowns, emollient range and selected wound care products to the offering allows more healthcare professionals and patients in the region to benefit from Mölnlycke products and solutions. Zlatko Rihter, CEO, Mölnlycke Health Care comments “To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.” Speaking on behalf of Tamer Group, Chairman Ayman Tamer adds “This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.” Mahmoud Wagih, CEO, Tamer Mölnlycke Care comments “I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.” The Tamer Mölnlycke Care joint venture is a long-term agreement between two organisations who have been working in partnership over the past decade; and are committed to meeting customer demand in the evolving healthcare landscape of Saudi Arabia and the wider region. For more information, please contact: Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics. Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com
Gothenburg 12 April 2024: Mölnlycke, a world leading MedTech company specialised in wound care and wound management, announced today it signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturising solutions. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, irrigation and moisturisation of various wound types. The high quality and composition of Granudacyn ensures good biocompatibility, allowing it to be effectively used on a broad range of tissues in burns, as well as acute and chronic wounds. Mölnlycke currently distributes Granudacyn in over 50 countries around the world. “With an ageing population in combination with increased chronic wounds, such as diabetic foot ulcers or venous leg ulcers, it is our obligation to help ease the burden of wounds on national healthcare regimes” says Zlatko Rihter, CEO of Mölnlycke Health Care. “The acquisition of P.G.F. and its state-of-the-art manufacturing plant, will allow Mölnlycke to aggressively expand our Granudacyn business to improve the lives of even more patients.” “I’m excited for P.G.F. to become part of Mölnlycke and for the team to continue to manufacture products that support Mölnlycke’s Wound Care mission to help free patients from the burden of wounds” says Peter Fritz, P.G.F. founder and CEO, who will continue to lead this team and manufacturing process from P.G.F.’s Austria headquarters. Closure is expected after certain milestones are reached and will be communicated separately. For more information, please contact: Jennifer Doak Global Communications Director Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 About Mölnlycke® Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter Fritz to develop and produce ecologically compatible hypochlorous acid based products to protect the user and their environment. The company is founded on more than 30 years of experience in research, development, production, and worldwide distribution of medical and measurement products. P.G.F. employs approximately 25 employees and is headquartered in Elixhausen, Austria. www.veriforte.com.
Performance highlights Mölnlycke reported strong growth in 2023, with net sales reaching EUR 1,924 million, an 8% increase in constant currency rates. The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic growth and market share gains across most markets. Sustainability achievements We made significant strides in operationalising our sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission reduction targets were validated by the Science Based Targets initiative. Noteworthy progress was made in our journey towards 100% fossil-free electricity by the end of 2024, with 61% fossil-free electricity share in 2023. We also achieved a 20% reduction in overall absolute greenhouse gas emissions across the entire value chain compared to the 2021 baseline. Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our portfolio in terms of net sales. Zlatko annual report news quote Innovation and quality highlights To enhance surgical performance, Mölnlycke introduced hand scanning technology using artificial intelligence and machine learning for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex® Border Post-Op product family globally and registered Hibiwash®, - the new colour- and fragrance-free Hibi formula. We also successfully completed the transition to Medical Device Regulation (MDR), one of the first MedTech companies to do so. Strategic investments Mölnlycke secured long-term financing through a EUR 400 million Eurobond and a EUR 350 million Revolving Credit Facility. We also decided to invest EUR 60 million to increase production capacity, including a new Mepilex Border Flex production line and a new Ethylene Oxide sterilisation unit in Finland.
The benchmarking procedure Mölnlycke are in the second year of working with EcoVadis as an independent and credible organisation to benchmark strengths and improvement opportunities. The rating process required extensive amounts of data and documentation, and therefore teamwork between global sustainability, legal and compliance, information technology, procurement excellence, and people experience teams. Our submission was assessed over a four week period. As a continuation from the previous assessment, results and feedback will be used to prioritise improvement plans. The result A gold medal is awarded to the all top 5%, and our score puts us into the top 3% of all organisations from all industries worldwide. Particularly recognized during the submission were Mölnlycke's commitment to Science Based Targets and measurable improvements in emissions, the strength of Mölnlycke procedures relating to human rights, demonstrable progress in gender equality, and the availability of the Ethics Hotline to all Mölnlycke's stakeholders The results certificate is available to download for verification below, EcoVadis will also provide a detailed validated scorecard to users of their platform.
The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB as mandated lead arrangers. SEB acted as the coordinator, documentation agent and facility agent for the transaction. For more information, please contact: Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics. Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com
Being born with a cleft lip or palate is more than just a cosmetic problem. Many children have issues eating or speaking. They can grow up isolated, unable to socialise and deprived of opportunities. The Philippines has one of the highest incidences of cleft palate and cleft lip in the world. A simple surgical procedure can correct cleft problems. But access to healthcare is low in the country, particularly for people living outside the two main islands, and there is a need to enhance the specialist cleft care skills of healthcare professionals. 10,000 surgeries in three years The centre, which is planned to open in Q4 2021, will serve the 27 million people who live on Cebu or one of the 150+ surrounding islands. In its first three years, Operation Smile and Mölnlycke estimate that the centre will support up to 10,000 surgeries, via a hub and spokes model in the community. More than 26,000 patients will receive consultations and 1,800 community health workers will be trained – alongside 400 Operation Smile volunteers and hospital staff. Supporting with funds, products and expertise Mölnlycke has committed to an initial three-year partnership agreement to support the centre at Cebu. In addition to funds, the company will donate products, train healthcare professionals in infection prevention and provide logistics support. As expertise within Cebu and the surrounding area grows, the ambition is for the centre to become less reliant on direct support and more self-sufficient. Zlatko cleft centre Quote Follow #Cebu10000 #Cebu10000 is the first time Mölnlycke has supported healthcare infrastructure and marks a significant step-change in the company’s relationship with its global charity partner Operation Smile. Since 2004, when Mölnlycke began its support of Operation Smile, the company has donated funds, volunteer time and more than 1.5 million pairs of Biogel® surgical gloves to support cleft procedures. A model of cleft care Bill Magee Cleft centre Quote Press contact Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com